Peroxiredoxin (Prx) 1 is a member of the thiol-specific peroxidases family and plays diverse roles such as H 2 O 2 scavenger, redox signal transducer and molecular chaperone. Prx1 has been reported to be involved in protecting cancer cells against various therapeutic challenges. We investigated how modulations of intracellular redox system affect cancer cell sensitivity to reactive oxygen species (ROS)-generating drugs. We observed that stable and transient Prx1 knockdown significantly enhanced HeLa cell sensitivity to β-lapachone (β-lap), a potential anticancer agent. Prx1 knockdown markedly potentiated 2 µM β-lap-induced cytotoxicity through ROS accumulation. This effect was largely NAD(P)H:quinone oxidoreductase 1 dependent and associated with a decrease in poly(ADP-ribose) polymerase 1 protein levels, phosphorylation of JNK, p38 and Erk proteins in mitogen-activated protein kinase (MAPK) pathways and a decrease in thioredoxin 1 (Trx1) protein levels. Trx1 serves as an electron donor for Prx1 and is overexpressed in Prx1 knockdown cells. Based on the fact that Prx1 is a major ROS scavenger and a partner of at least ASK1 and JNK, two key components of MAPK pathways, we propose that Prx1 knockdown-induced sensitization to β-lap is achieved through combined action of accumulation of ROS and enhancement of MAPK pathway activation, leading to cell apoptosis. These data support the view that modulation of intracellular redox state could be an alternative approach to enhance cancer cell sensitivity to ROS-generating drugs or to overcome some types of drug resistance.
Introduction
Peroxiredoxins (Prxs) constitute a family of thiol-specific peroxidases that utilize cysteine as the primary site for oxidation during the reduction of peroxides (1) . Prx1 is the most abundant among the six isoforms of human Prxs and utilizes thioredoxin 1 (Trx1) as an electron donor (2) . Prx1 is able to regulate hydrogen peroxide (H 2 O 2 ) levels, an important signaling molecule, through several mechanisms. As a peroxidase, Prx1 reduces directly H 2 O 2 to H 2 O. Prx1 overoxidation and consequent loss of peroxidase activity allows accumulation of H 2 O 2 to substantial levels to function as a signal (3) . Phosphorylation of Prx1 and reversible loss of peroxidase activity provides another mechanism that allows transient accumulation of H 2 O 2 for receptor signaling (4) . Importantly, in addition to its direct peroxidase activity, Prx1 modulates related signaling pathways via interacting with proteins such as glutathione-S-transferase pi/c-Jun N-terminal kinase complex, apoptosis signal-regulating kinase 1 (ASK1), Abelson tyrosine kinase (c-Abl), androgen receptor, c-myc, macrophage migration inhibitory factor (MIF), p66 Src homolog and collagen homolog (p66Shc), presenilin-1, mammalian ste20-like kinase 1, phosphatase and tensin homolog and Toll-like receptor 4 (4-6). Elevated expression of Prx1 has frequently been found in various cancer cells including lung, bladder, liver, thyroid and breast cancers (7) (8) (9) (10) . Prx1 is responsible for cell resistance to TRAIL or cisplatin (11, 12) and it is generally thought that dysregulation of intracellular Prxs and particularly Prx1 is associated with carcinogenesis, metastasis and resistance to radiotherapy or chemotherapy (7, 10, 11) . However, the underlying molecular mechanisms remain unclear.
β-Lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho [1,2-b] pyran-5,6-dione; β-lap), a natural quinone obtained from the bark of the Lapacho tree (Tabebuia vellanedae), has been reported to exert a variety of pharmacological activities. β-Lap possesses antitumor properties toward a broad spectrum of cancers including human breast and prostate cancer (13, 14) , myeloid leukemia (15) , lung cancer (16) , hepatoma (11) , glioma (17) and pancreatic cancer (18) . The molecular mechanisms underlying the anticancer activity of β-lap appear to be multifaceted but have not yet been clearly delineated. It is known that the futile cycling of β-lap catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) using NADH or NADPH as an electron source leads to progressive NADH or NADPH depletion, which in turn induces massive Ca 2+ release from the endoplasmic reticulum to the cytosol, causing activation of calpain and subsequent apoptosis (19) . In addition, β-lap treatment leads to massive reactive oxygen species (ROS) production (17) , activation of mitogen-activated protein kinases [MAPKs (20, 21) ], induction of endoplasmic reticulum stress (21) , activation of the S-phase checkpoint (22) , inhibition of DNA damage repair via hyperactivation of poly(ADP-ribose) polymerase 1 [PARP1 (23) ] and activation of caspase-dependent or independent pathways (15, 24, 25) . Better insights into the molecular mechanisms and signaling pathways underlying the anticancer activity of β-lap will improve treatment strategies using this potential novel drug.
Generation of ROS by β-lap appears to play a key role in initiating cascades of cell death signals. The ROS scavenging capacity and the cell signal modulation role of Prx1 prompted us to investigate the effect of its knockdown on cellular sensitivity to several ROSgenerating agents, including β-lap. We found that Prx1 knockdown significantly potentiated 2 µM β-lap-induced cytotoxicity. We propose that Prx1 knockdown-mediated ROS accumulation and facilitated activation of the MAPK pathways could be two principal mechanisms conferring high cellular sensitivity to low-dose β-lap.
Materials and methods
Reagents β-Lap, H 2 O 2 , 2-phenylethyl isothiocyanate (PEITC), N-acetyl-l-cysteine (NAC), dicoumarol (DIC), dl-buthionine-(S,R)-sulfoximine (BSO), dimethyl sulfoxide (DMSO), dithiothreitol, trichloroacetic acid and crystal violet were purchased from Sigma-Aldrich. Hygromycin B, 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H 2 DCFDA), dihydroethidium (DHE), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Vybrant Apoptosis Assay Kit #3, propidium iodide (PI), tetramethylrhodamine methyl ester (TMRM) and 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid were from Invitrogen. Inhibitors specific to JNK (SP600125), p38 MAPK (SB203580) and Erk (PD98059) were from Calbiochem. The following antibodies were purchased: Prx1 (AbFrontier); NQO1 (Abcam); β-actin Abbreviations: ASK1, apoptosis signal-regulating kinase 1; AV, Annexin V; BSO, dl-buthionine-(S,R)-sulfoximine; carboxy-H 2 DCFDA, 6-carboxy-2ʹ,7ʹ-dichlorodihydrofluorescein diacetate; DHE, dihydroethidium; DIC, dicoumarol; DMSO, dimethyl sulfoxide; H 2 O 2 , hydrogen peroxide; β-lap, β-lapachone; MAPK, mitogen-activated protein kinase; MMP, mitochondrial membrane potential; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NAC, N-acetyl-l-cysteine; NQO1, NAD(P)H:quinone oxidoreductase 1; PARP1, poly(ADP-ribose) polymerase 1; PEITC, 2-phenylethyl isothiocyanate; PI, propidium iodide; Prx, peroxiredoxin; qRT-PCR, quantitative real-time PCR; ROS, reactive oxygen species; siRNA, small interfering RNA; TMRM, tetramethylrhodamine methyl ester; Trx1, thioredoxin 1.
Prx1 knockdown potentiates β-lapachone cytotoxicity
(Sigma-Aldrich); α-tubulin (Santa Cruz Biotechnology); caspase-3, caspase-9, PARP1, JNK, p38, Erk, phospho-JNK, phospho-p38, phospho-Erk and Trx1 (all from Cell Signaling Technology). ON-TARGETplus SMARTpool siRNA targeting PRX1 (siPrx1), NQO1 (siNQO1) and non-targeting pool control siRNA (siCon) were from Dharmacon. siRNA transfection reagent INTERFERin was from Polyplus.
Cell culture
Human cervical adenocarcinoma HeLa cells stably knocked down for PRX1 gene (PRDX1 HeLa SilenciX, designated as Prx1− cells) and non-silencing control cells (Control HeLa SilenciX, designated as Prx1+ cells) were purchased from tebu-bio and were cultured in standard Dulbecco's modified Eagle's medium supplemented with 50 µg/ml hygromycin B. Non-engineered HeLa, human lung cancer A549 and breast cancer MCF-7 cell lines were from ATCC. Non-engineered HeLa and A549 cells were maintained in Dulbecco's modified Eagle's medium. MCF-7 cells were cultured in standard Eagle's minimum essential medium.
Quantitative real-time PCR
Total RNA was isolated with RNeasy protect mini kit (Qiagen). cDNA was generated using iScript cDNA Synthesis Kit (Bio-Rad). Specific primer pairs for PRX1 and ACTB were from SABiosciences. Forward and reverse primers for NQO1 and PARP1 were synthesized according to the sequence described previously (26, 27) . ACTB served as reference gene for relative quantification. Quantitative real-time PCR (qRT-PCR) was performed with iQ SYBR Green Supermix (Bio-Rad) in a CFX96 real-time PCR detection system (Bio-Rad). Cells (5 × 10 3 ) were plated in 60 mm dishes and cultured at 37°C overnight. Cells were then treated with indicated doses of β-lap or DMSO (vehicle control) for defined times followed by incubation in fresh medium for another 5 days. The cells were then fixed and stained with 0.05% crystal violet in 70% ethanol. The number of visible colonies was counted manually.
MTT-based cell viability assay and PI-based cell death assay

Cell clonogenic assay
Small interfering RNA transfection
For small interfering RNA (siRNA) transfection, cells were seeded at density of 5 × 10 3 per well into a 96-well plate or at 1 × 10 5 per well into a 6-well plate the day before transfection. Cells were then transfected with 5 nM siRNA using INTERFERin transfection reagents according to the manufacturer's instructions. Further experiments were performed 48 h after transfection.
Cell apoptosis detection by flow cytometry
Fluorescent isothiocyanate-conjugated Annexin V (AV)/PI colabeling was performed using the Vybrant Apoptosis Assay Kit #3 according to the manufacturer's instructions. Cells were analyzed in FL1-H (fluorescent isothiocyanate) and FL2-H (PI) channels on flow cytometer.
Measurement of intracellular ROS production and mitochondrial membrane potential
The level of intracellular ROS was determined using general redox sensitive carboxy-H 2 DCFDA or DHE, which is more selective for superoxide anions. Briefly, cells were trypsinized, resuspended in medium without phenol red and serum and stained with 10 µM carboxy-H 2 DCFDA or 5 µM DHE for 30 min at 37°C in the dark. The cells were then washed in PBS, collected and analyzed immediately by flow cytometry. Mitochondrial membrane potential (MMP) was monitored using TMRM. Cells were washed with PBS and incubated with 10 nM TMRM for 30 min at 37°C before being analyzed by flow cytometry.
NQO1 enzymatic activity analysis NQO1 enzymatic activity analysis was performed as described previously and is based on the principle that NQO1 catalyzes the reduction of menadione to menadiol using NADH as electron donor and the resulting menadiol reduces MTT to a purple formazan that can be quantitatively determined by its characteristic absorbance (28, 29) . Absorbance A 595 of final reaction products in 96-well plates was measured with a multiwell spectrophotometer as for the MTT assay.
Western blotting and redox western blotting
For classic western blotting, cells were lysed in M-PER protein extraction reagent (Pierce) supplemented with 0.5 mM dithiothreitol and complete protease inhibitor cocktail (Roche Molecular Biochemicals) according to the instructions. Lysates were resolved by 12% NuPAGE Novex Bis-Tris gel with 3-(N-morpholino)propanesulfonic acid buffer (Invitrogen) under reducing condition and transferred onto nitrocellulose membranes that were then probed with the given primary antibody. Redox western blot analysis for Trx1 redox state was adapted from previously described methods (30) with slight modifications. Briefly, cells in culture were acid quenched with ice-cold 10% trichloroacetic acid for 30 min and harvested by centrifugation. Pellets were washed with acetone and dry pellets were dissolved in lysis buffer (100 mM Tris-HCl, 1% sodium dodecyl sulfate, 10 mM ethylenediaminetetraacetic acid, pH 8.8) supplemented with 10 mM 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid. Following 1 h incubation at 37°C, insoluble protein was removed by centrifugation. Each sample containing about 30 μg of protein was separated on a 12% NuPAGE Novex Bis-Tris gel with 2-(N-morpholino)ethanesulfonic acid buffer (Invitrogen) under non-reducing condition. After transfer to a nitrocellulose membrane, reduced and oxidized forms of Trx1 were probed with an anti-Trx1 antibody. For both classic and redox western blotting, blots were washed and probed with IRDye 680 or IRDye 800cw conjugated secondary antibody (IRDye, LI-COR) and then analyzed using an Odyssey Infrared Imaging System (LI-COR). Scanned images and band integrated intensity were analyzed and quantified by Odyssey v3.0 software.
Results
Prx1 knockdown confers sensitivity to β-lap
Prx1 is widely thought to play protective roles against ROS insults and therapeutic challenges. We, therefore, investigated the effect of Prx1 knockdown on cellular sensitivity to several ROS-generating agents. For this purpose, we used a commercially available HeLa cell line with the PRX1 gene stably knocked down (Prx1−) and a corresponding control cell line (Prx1+). The efficiency of Prx1 knockdown was confirmed by qRT-PCR and western blot ( Figure 1A ). Prx1+ and Prx1− cells were exposed to four ROS-generating chemicals, including H 2 O 2 , β-lap, BSO [a glutathione synthesis inhibitor (31)] and PEITC [glutathione depletion and ROS-inducing agent (32) ]. Based on MTT assay, Prx1− cells exhibited a significant, highly reproducible increased sensitivity to β-lap, but not to H 2 O 2 , BSO or PEITC, compared with Prx1+ cells ( Figure 1B ). After treatment with 2 µM β-lap for 24 h, cell viability for Prx1− cells was ~8% compared with ~60% for Prx1+ cells. In contrast, cell viability was found to be <10% for both Prx1− and Prx1+ cells after treatment with 5 µM β-lap for 24 h. Preferential cell death was also observed in Prx1− cells treated with 2 or 5 µM β-lap for 4 h ( Figure 1B) . PI-based cell death assay confirmed enhanced cell sensitivity to β-lap in which >83% of Prx1− cells became PI + compared with <5% of Prx1+ cells after treatment with 2 µM β-lap for 24 h ( Figure 1D ). We performed a clonogenic assay to further confirm enhanced β-lap cytotoxicity in Prx1− cells. Consistently but more remarkably than shown by MTT and PI assays above, β-lap at the concentration of 2 or 5 µM preferentially inhibited colony formation of Prx1− cells treated from 4 to 24 h ( Figure 1E ). The clonogenic ratio of Prx1− cells was ~27% compared with ~92% in Prx1+ cells upon exposure to 2 µM β-lap for 4 h, and ~0% versus ~87% after β-lap treatment for 16 h. Longer β-lap exposure also led to a decreased colony formation in Prx1+ cells.
To further demonstrate the relationship between enhanced cell sensitivity to β-lap and Prx1 knockdown, we examined cell sensitivity to β-lap in non-engineered HeLa cells with transient Prx1 depletion using siRNA targeted to Prx1 sequences different to those in the stable cell line. The efficiency of Prx1 knockdown was determined by western blot analysis ( Figure 1C ). Under various treatments, β-lap was also found to induce more death in Prx1 transiently knockeddown cells than control cells transfected with non-targeted control siRNA. Therefore, both stable and transient Prx1 knockdown potentiated cell sensitivity to β-lap. We then extended similar analysis Figure 1F ). Enhanced β-lap toxicity after Prx1 transient silencing was observed in both cell lines, with a less remarkable effect than that in HeLa Prx1− cells, very probably due to less efficient transient Prx1 knockdown (~70% versus ~ 90% silencing in stable knockdown HeLa Prx1− cells).
Prx1 knockdown increases ROS accumulation in response to β-lap
ROS have been linked to β-lap-induced cell death in many cancer cell types (17, 18, 20) . To determine cellular ROS level in response to β-lap, both Prx1+ and Prx1− cells were treated with β-lap for 4 h and then incubated for 30 min with 10 µM carboxy-H 2 DCFDA. As shown in Figure 2A , untreated Prx1− cells did not exhibit fluorescence intensity shift compared with untreated Prx1+ cells, whereas increased fluorescence intensity was detected in Prx1− cells treated with 2 µM β-lap, indicating an increased ROS accumulation. In contrast, no detectable ROS induction was observed in Prx1+ cells treated under the same conditions. Similar results were obtained using DHE probe ( Figure 2B ). In the presence of 5 µM β-lap, remarkably increased fluorescence intensity was observed in both Prx1− and Prx1+ cells. It is interesting to note that the ROS accumulation in response to 2 µM β-lap in Prx1− cells, although less elevated than that induced by 5 µM β-lap in Prx1+ and Prx1− cells, is sufficient to trigger cell death in Prx1− cells. To investigate the involvement of ROS in β-lapinduced cell death, we examined the effect of the general ROS scavenger NAC. As shown in Figure 2C , NAC significantly alleviated 2 µM β-lap-induced Prx1− cell death. It also partially alleviated 5 µM β-lapinduced Prx1+ but not Prx1− cell death. Taken together, we conclude that increased ROS accumulation in Prx1− cells by low-dose β-lap is closely associated with its enhanced cellular cytotoxicity.
Enhanced sensitivity to 2 µM β-lap in Prx1− cells relies on NQO1 activity
Previous studies have demonstrated that NQO1 activity is an important determinant of β-lap cytotoxicity in various cell lines (24) . To determine whether β-lap cytotoxicity in Prx1− cells is dependent on NQO1 activity, Prx1+ and Prx1− cells were pretreated with DIC, a NQO1-specific inhibitor (33), then exposed to β-lap. As shown in Figure 3A , DIC attenuated significantly 2 µM β-lap-induced Prx1− cell death and 5 µM β-lap-induced Prx1+ cell death, whereas it showed no such effect on 5 µM β-lap-triggered Prx1− cell death. Interestingly, DIC effectively eliminated increased ROS accumulation in 2 µM β-laptreated Prx1− cells and 5 µM β-lap-treated Prx1+ cells, but not in 5 µM β-lap-treated Prx1− cells ( Figure 3B ), which correlates with its inhibitory effect on cell death. NQO1 knockdown by siRNA confirmed that NQO1 activity is involved in low-dose (2 µM) β-lap cytotoxicity ( Figure 3C ). However, Prx1 knockdown did not significantly modify the expression and enzymatic activity of NQO1 ( Figure 3D ).
Enhanced sensitivity to 2 µM β-lap in Prx1− cells involves caspaseindependent apoptosis
We assessed whether apoptosis pathways and caspase activation are involved in enhanced cell sensitivity to β-lap caused by Prx1 knockdown. β-Lap-treated Prx1+ and Prx1− cells were subjected to flow cytometry based analysis following AV/PI double staining or TMRM staining ( Figure 4A and B) and western blot analysis with anti-caspase-3, caspase-9 and PARP1 antibody ( Figure 4C -E). Treatment with 2 µM β-lap for 16 h caused ~60% of Prx1− cells with apoptotic response (AV + /PI -and AV + /PI + ), against only <6% of Prx1+ cells ( Figure 4A ). TMRM staining allows monitoring MMP loss, which is a key early event in the process of apoptosis (15) . As shown in Figure 4B , consistently, >80% of Prx1− cells showed loss of MMP after treatment with 2 µM β-lap for 12 h compared with <7% of Prx1+ cells. Higher proportions of AV + and MMP loss in β-lap-treated Prx1− cells indicate that enhanced sensitivity of Prx1− cells to β-lap involves activation of apoptosis pathways. However, no cleavage of caspase-3 ( Figure 4C ) and caspase-8 (data not shown) was detectable in Prx1− cells under these treatments, implying no participation of classic caspase-dependent apoptotic pathways. Caspase-9 was only slightly cleaved upon treatment of 5 µM β-lap in both Prx1+ and Prx1− cells or upon treatment of 2 µM β-lap in Prx1− cells (Figure 4D ), suggesting that caspase-9 may contribute partially to enhanced cell sensitivity to β-lap.
There has been an inconsistency regarding the involvement of PARP1 in β-lap cytotoxicity (17, 23, 34) . Therefore, we monitored PARP1 expression and its possible cleavage products in β-lap-treated Prx1+ and Prx1− cells. A significant decrease of PARP1 protein levels was detected in Prx1+ cells treated with 5 µM β-lap and in Prx1− cells treated with 2 or 5 µM β-lap ( Figure 4E, left panel) . These reduced PARP1 protein levels were not due to decreased PARP1 transcription since the mRNA levels in Prx1+ and Prx1− cells were unchanged following the same treatment ( Figure 4E, right panel) . No cleavage products were detected after 2 or 5 µM treatment from 1 to 4 h. In addition, NQO1 inhibitor DIC restored decreased levels of PARP1 in 5 µM β-lap-treated Prx1+ cells and 2 µM β-lap-treated Prx1− cells, but not in 5 µM β-lap-treated Prx1− cells, which correlated well with DIC inhibitory effects on β-lapinduced cell death ( Figure 3A ), implying a relationship between PARP1 levels and β-lap-induced cell death. These observations suggest that, under the present experimental conditions, 2 µM β-lap cytotoxicity to Prx1− cells is associated with decreased PARP1 protein levels.
Prx1 knockdown facilitates MAPK activation in response to β-lap treatment
The involvement of MAPKs including JNK, p38 and Erk in β-lapinduced cell death has been reported (20, 35, 36) . To determine whether Prx1 knockdown alters MAPK pathway signaling in response to β-lap, Prx1+ and Prx1− cells were treated with β-lap and then subjected to western blot analysis with anti-JNK, anti-phospho-JNK, anti-p38, anti-phospho-p38, anti-Erk1/2 and anti-phospho-Erk1/2 antibodies. As shown in Figure 5A , total JNK, p38 or Erk level remained unchanged throughout β-lap treatment. In contrast, high levels of JNK and p38 phosphorylation were observed in Prx1− cells upon 2 and 5 μM β-lap treatment, whereas in Prx1+ cells, similar phosphorylation was observed only following 5 μM β-lap treatment. Furthermore, Prx1− cells exhibited remarkable Erk1/2 phosphorylation in the presence of 2 and 5 μM β-lap for 4 h, whereas Prx1+ cells showed no such phosphorylation after these treatments. These data suggest that sensitivity of Prx1− cells to 2 μM β-lap is associated with enhanced JNK, p38 and Erk phosphorylation. To further determine the involvement of MAPKs in β-lap-induced cell death processes, we pretreated cells for 1 h with SP600125 (JNK inhibitor), SB203580 (p38 inhibitor) or PD98059 (Erk inhibitor), followed by cotreatment with β-lap and the respective inhibitor for 4 h ( Figure 5B ). Interestingly, JNK inhibitor significantly reduced 5 μM β-lap-and 2 μM β-lap-induced cell death in Prx1+ and Prx1− cells, respectively, but failed to reduce 5 μM β-lap-induced cell death in Prx1− cells. p38 inhibitor failed to attenuate β-lap-induced cell death in both Prx1+ and Prx1− cells. Erk inhibitor significantly reduced Prx1+ cell death by 5 μM β-lap but failed to block Prx1− cell death induced by 2 or 5 μM β-lap. These data indicate that under the current experimental conditions, JNK activation is largely responsible for the enhanced cytotoxicity of 2 μM β-lap in Prx1− cells. However, we cannot exclude involvement of Erk and p38 activation in these processes. Thus, Prx1 knockdown appears to predispose the cells to the activation of MAPK signaling pathways ← after low-dose (2 μM) β-lap, which is attainable only by higher dose (5 μM) β-lap treatment in Prx1+ cells.
Trx1 overexpression in Prx1− cells is suppressed in response to β-lap
Trx1 is a direct electron donor for Prx1. Moreover, Trx1 directly interacts with ASK1, a MAP3K protein that activates JNK/p38-mediated apoptosis in response to environmental stresses such as ROS (37) . We investigated whether Prx1 knockdown could influence Trx1 expression and its redox state in response to β-lap. A redox western blot was performed to evaluate ratio of oxidized and reduced forms of Trx1 upon β-lap treatment. As shown in Figure 5C , total Trx1 protein level (sum of oxidized and reduced forms), mostly in reduced form, was significantly elevated in Prx1− cells compared with Prx1+ cells, probably as an adaptive response to Prx1 knockdown. Exposure to 2 or 5 μM β-lap for 4 h significantly decreased Trx1 protein levels in Prx1− cells, probably due to export of oxidized Trx1 outside the cell (38) . Furthermore, Trx1 in both Prx1+ and Prx1− cells underwent similar oxidation shifts upon β-lap treatment. As reduced Trx1 inhibits ASK1 kinase activity through protein interaction (39), decreased protein levels and increased oxidation of Trx1 may facilitate the release of ASK1 from Trx1-ASK1 complex and activate ASK1, consequently activating downstream MAPKs.
Discussion
Prx1 is considered a major ROS scavenger, particularly of H 2 O 2 . We expected that cells with lower Prx1 levels would display enhanced sensitivity to ROS-generating reagents. Surprisingly, Prx1 knockdown significantly potentiated cellular sensitivity to 2 µM β-lap toxicity but not to H 2 O 2 , BSO or PEITC. The reasons for this specificity could be multiple. H 2 O 2 , extensively used as an exogenous oxidative stress-inducing agent, efficiently kills HeLa Prx1+ or Prx1− cells without difference. Exogenously introduced low dose of H 2 O 2 could be efficiently catabolized by intracellular antioxidants including other Prxs and catalases even in the absence of Prx1. Cytotoxic doses of H 2 O 2 could overwhelm the overall antioxidant systems in both Prx1+ and Prx1− cells and trigger cell death. On the other hand, BSO inhibits the synthesis of glutathione and partially depletes cellular glutathione. However, residual glutathione in BSO-treated cells is sufficient to maintain cell growth, and consequent ROS accumulation following glutathione depletion is not sufficient to trigger cell death. Finally, PEITC also induces ROS stress through affecting intracellular glutathione levels by conjugating and exporting glutathione outside the cells (40) (41) (42) . The lack of alterations in sensitivity between Prx1− and Prx1+ cells in response to BSO and PEITC suggests that Prx1 knockdown may not significantly impact the capacity of the glutathione antioxidant system involving glutathione, glutathione peroxidases, glutathione reductases and glutaredoxins. Taken together, H 2 O 2 , BSO or PEITC treatment may fail to attain the localized elevated ROS level essential for triggering preferential cell death in the context of Prx1− cells. In contrast, ROS generation during NQO1-mediated metabolism of β-lap could be localized in some subcellular regions where local Prx1 plays a key role in detoxification. Consistently, it has been demonstrated that Prx1 associated with membranes is transiently phosphorylated on a tyrosine residue and is thereby inactivated in cells stimulated by growth factor or immune receptors, allowing transient accumulation of H 2 O 2 around membranes for cell signaling, where signaling components are concentrated (43) . Taking into account the fact that cytotoxic effects of 2 µM β-lap in Prx1− cells and 5 µM β-lap in Prx1+ cells are NQO1 dependent, we propose that ROS elevation following low-dose β-lap treatment could be derived from combined effect of ROS generation during β-lap metabolism by NQO1 and diminished Prx1 scavenging activity. The finding that NQO1 inhibition did not alleviate 5 µM β-lap-induced cell death or block ROS accumulation in Prx1− cells suggests that ROS generation in response to higher dose β-lap could involve other mechanisms and other sources. Among those to be considered include β-lap metabolic pathways mediated by NRH:quinone oxidoreductase 2, and intracellular ROS generators such as NADPH oxidases and mitochondria (11, 41) .
In addition to ROS, other cell signaling molecules modulated by Prx1 could participate or have a great impact on cytotoxicity of β-lap (4-6). For instance, Prx1 interacts with the glutathione-S-transferase pi/c-Jun N-terminal kinase complex and suppresses the release of JNK from this complex, preventing ionizing radiation-induced JNK activation and apoptosis (16) . Prx1 interacts with ASK1, and its overexpression inhibits ASK1 activation (44) . Prx1 also binds p66Shc, a central player in stress-induced apoptosis and ROS amplification, to form a stress-sensing complex that keeps p66Shc inactive as long as stress levels remain moderate, preventing mitochondrial disintegration and the initiation of the mitochondrial apoptosis pathway (45) . On the other hand, H 2 O 2 -induced Prx1 oxidation results in formation of Prx1 homo-oligomers that could interact with mammalian ste20-like kinase 1, leading to mammalian ste20-like kinase 1 activation by autophosphorylation and cell death (5) . Therefore, in the present context, it is conceivable that Prx1 knockdown facilitates stress-induced activation of ASK1, JNK and/or other partners. Indeed, although we failed to detect the presence of native total or phospho-ASK1 using commercially available antibodies, all MAPKs, JNK, p38 and Erk were found highly phosphorylated soon after 2 µM β-lap treatment, a dose not sufficient to activate MAPKs in Prx1+ cells. In particular, inhibition of JNK by a specific inhibitor effectively attenuates 2 µM β-lap-induced cell death in Prx1− cells, suggesting that JNK activation plays a critical role in mediating low-dose β-lap-induced cell death in Prx1− cells. The significance of Erk and p38 activation in response to β-lap requires further studies. Trx1 is another player that is most probably involved in enhanced cytotoxicity of β-lap in Prx1− cells. As an electron donor to oxidized Prx1 (sulfenic acid forms), Trx1 plays a key role in maintaining a large number of redox sensitive proteins in a reduced state and protects them from inactivation or degradation (46) . Importantly, the reduced form of Trx1 binds ASK1 and p38, thus preventing them from stress-induced activation (38, 47) . We observed that Prx1 knockdown induces accumulation of total Trx1, suggesting an adaptive mechanism for cells to maintain redox balance. In response to β-lap treatment, elevated Trx1 levels are significantly decreased, which could disrupt the adaptive redox balance, facilitating activation of ASK1 and p38. Taken together, these data suggest that Prx1 knockdown significantly enhances β-lap cytotoxicity through modulating several factors in the MAPK pathway, leading to cell apoptosis.
The downstream events and signal pathways that lead to apoptotic cell death in response to β-lap remain controversial in the literature, in part due to the β-lap doses and cell lines used. Both caspase-dependent A representative blot out of three independent experiments is shown. Trx1 signals in the two cell lines were from the same blot and same exposure. α-Tubulin on the same blot was used as a loading control. Normalized total Trx1 levels (Trx1 red + Trx1 ox ) in Prx1+ cells without β-lap treatment is set as 1. Percentage of oxidized Trx1 = Trx1 ox intensity/total Trx1 intensity × 100. Data are the mean ± SD of at least three independent experiments. The statistical significance is calculated by the Student's t-test. *P < 0.05. and -independent cell death have been described (15, 24) . Caspase activation was reported to be involved in β-lap-induced apoptotic cell death of breast cancer cells (14) . Other authors privileged caspaseindependent pathways that involve nuclear translocation of apoptosisinducing factor and endonuclease G or activation of non-apoptotic pathways such as autophagy (17) . Some studies provide evidence that β-lap-induced apoptosis is a unique proteolytic apoptotic pathway in NQO1-expressing cells via µ-calpain activation, which cleaves PARP1 to a unique fragment, leading to PARP1 inactivation (34) . Other authors reported that β-lap induces Ca 2+ -dependent PARP1 hyperactivation shortly after treatment and depletes NAD + and ATP, thereby, inactivating energy-dependent DNA repair processes (23, 48) . In the present study, no caspase-8 and caspase-3 cleavage and only slight caspase-9 cleavage were observed in 5 µM β-lap-treated Prx1+ cells or in 2 and 5 µM β-lap-treated Prx1− cells, favoring the view of caspase-independent apoptosis. In contrast, β-lap treatment decreased PARP1 protein levels in Prx1+ cells (5 µM β-lap) and in Prx1− cells (2 and 5 µM β-lap). The significance of reduced PARP1 protein levels in β-lap-induced cell death remains to be determined, but probably leads to defective DNA repair, and/or a shift from necrosis to apoptosis (49, 50) .
In conclusion, in the present study, we show that Prx1 knockdown significantly enhances β-lap cytotoxicity through modulating ROS accumulation and MAPK activation ( Figure 6 ). Better insights into the mechanisms accounting for Prx1 knockdown-induced sensitization to β-lap will lead to better understanding of redox regulation involving Prxs and to advancement in cancer treatment strategies using β-lap. More generally, these data support the view that modulation of intracellular redox states could be an alternative approach to enhance cancer cell sensitivity to ROS-generating drugs or to overcome some types of drug resistance.
Funding
Centre National de la Recherche Scientifique (CNRS), Institut Curie and Comité de l'Essonne de la Ligue Nationale Contre le Cancer (to M.E.H.). Tiantian He is supported by a PhD fellowship from the China Scholarship Council. Fig. 6 . Proposed mechanisms for enhanced cytotoxicity of low-dose β-lap in Prx1− cells. Prx1 is the first line of defense against ROS generated during cellular metabolism of β-lap mediated by NQO1. Prx1 also interacts with Trx1, ASK1, JNK, and probably other factors and prevents activation of signal molecules in the MAPK pathway. Consequently, Prx1 knockdown could affect at least these two processes, conferring enhanced sensitivity to low-dose β-lap. In addition, reduced PARP1 protein level following β-lap treatment could contribute to massive DNA damage and tilt β-lap-induced cell death from necrosis to apoptosis.
